

## novel therapeutic approaches for EBV-related LPD

C. Rooney (Houston) discussed EBV-specific T-cell therapy for patients with chronic and persistent EBV infection. In Western populations (e.g. United States, Europe) these patients usually have expansion of EBV-infected B cells, i.e. the B-cell type of CAEBV. Historical therapeutic approaches, before the use of bone marrow or stem-cell transplantation, have included high-dose immunoglobulin, IL-2, antiviral agents, IFN- $\alpha$  or IFN- $\gamma$ , corticosteroids, and rituximab. Other than isolated case reports, these therapies generally have not been successful and relapses were common. More recently autologous EBV-specific T cells have been used in the therapy of persistent active EBV infection [54]. This therapy also has been successful in the post-transplant setting [55]. Incubation of the patient's peripheral blood mononuclear cells with their irradiated EBV-transformed B cells results in activation of EBV-specific T cells in all seropositive donors, including both healthy persons and those with EBV-associated LPDs. In some cases, however, generation of EBV-transformed B cells may be difficult or impossible if the patient received rituximab within the prior 6 months or high doses of chemotherapy. The induced activated EBV-specific T cells recognize EBV EBNA-3A, 3B, and 3C and early-lytic antigens to a greater extent than T cells that recognize LMP1, LMP2, or EBNA-1.


A phase I study was reported using autologous EBV-specific T cells in patients with mild CAEBV defined as >6 months of symptoms (most often fever and fatigue) and either elevated peripheral blood EBV load or free EBV DNA in serum/cerebrospinal fluid or EBV VCA antibody titer >1 : 640 [54]. The study showed improvement or resolution of symptoms and the follow-up on these patients is now 2–6 years. Many of these patients have had normalization or reduction of their EBV VCA antibody titers, a decrease in the EBV DNA load, and an increase in circulating EBV-specific CTLs after therapy. Additional patients have now been enrolled with severe CAEBV

involving B or T cells; while some of these patients have shown clear responses to therapy, other have required hematopoietic stem-cell transplantation. Newer techniques are being developed to target additional EBV proteins, particularly LMP1, LMP2, and EBNA-1. Adenovirus vectors have been used to infect both dendritic cells and EBV-transformed B cells to enrich for the frequency of these antigens as targets for the patient's peripheral blood mononuclear cells [56, 57] (Figure 4). Adenovirus expressing EBV LMP2 has been used to generate LMP2-specific autologous CTLs in a clinical trial in patients with EBV-positive lymphomas [58]. Most patients with relapsed disease had a complete response to the CTLs.

H. Heslop (Houston) discussed the use of hematopoietic stem-cell transplantation for treatment of CAEBV. This approach has been used in children with hemophagocytic lymphohistiocytosis (HLH), a hereditary disorder that shares many features with CAEBV [59]. As with CAEBV, most of the deaths are related to early complications of transplantation [38]. More recent studies in HLH using reduced intensity conditioning with fludarabine, melphalan, and alemtuzumab have resulted in improved survival rates of 75%–93% at 1 year [60], as compared with fully ablative transplantation.

Transplantation for CAEBV has resulted in survival rates of 50%–64%. Younger patients, those with lower viral loads and those with less intense conditioning regimens have had improved survival [30]. A number of strategies are being considered to reduce the risk of relapse including the use of additional boosts of EBV-specific T cells after transplant, infusions of T cells that recognize antigens on lymphoma cells (e.g. CD70), or enhancing alloreactivity through the use of antibodies that can link tumor cells and CTLs by binding both tumor cell antigens and antigen receptors on CTLs.

W. Wilson (Bethesda) discussed the use of novel therapies for EBV LPD. Antiviral therapy may have some activity, particularly at an early stage when virus replication is more prominent. A study of valganciclovir in 47 children with EBV infection after liver transplantation showed a reduction in EBV



**Figure 4.** Generation of cytotoxic T cells that recognize EBV LMP2. Autologous dendritic cells and EBV-transformed B cells [lymphoblastoid cell line (LCL)] are infected with adenovirus expressing LMP2 (Ad5f35). These cells are used to present LMP2 to peripheral blood mononuclear cells (PBMCs). After stimulation of PBMCs with irradiated adenovirus-infected dendritic cells and LCLs in the presence of IL-2, LMP2-specific autologous cytotoxic T cells (CTLs) are obtained [58].

viral load and no new cases of post-transplant LPD [61]. Histone deacetylase inhibitors, such as sodium butyrate induce viral gene expression with lytic EBV replication. These agents induce expression of the viral thymidine kinase which can phosphorylate ganciclovir which is toxic to cells [62]. A recent clinical trial using arginine butyrate and ganciclovir resulted in improved survival [63]. High-dose sodium butyrate and ganciclovir can block the phosphatidylinositol-3-kinase/Akt pathway to kill virus-infected cells. Valproic acid is a potent histone deacetylase inhibitor and induces lytic EBV gene expression. Combination therapy of valproic acid with gemcitabine kills EBV-transformed B cells *in vitro* and in SCID mice more effectively than chemotherapy alone [64, 65]. EBV-transformed B cells show activation of NF- $\kappa$ B, and bortezomib, a proteasome inhibitor, leads to increased levels of I $\kappa$ B kinase and inhibits activation of NF- $\kappa$ B. EBV LMP1 inhibits apoptosis to prevent death of transformed B cells. HA14-1 is a small molecule inhibitor of Bcl-2 that kills EBV-transformed B cells [66]. The combination of bortezomib and HA14-1 was synergistic for killing EBV-transformed B cells *in vitro*. Another NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin induced apoptosis of EBV-transformed B cells [67]. The mammalian target of rapamycin pathway is another target for killing EBV-transformed B cells. Inhibition of this pathway affects multiple downstream signaling molecules required for protein synthesis and cell cycle progression. Rapamycin kills EBV-transformed B cells *in vitro* and in SCID mice [68]. Thus, the study of molecular pathways activated in EBV-transformed B cells has led to candidates for the treatment of EBV LPD.

## conclusions

The lack of understanding of uncommon EBV LPDs affecting B cells, T cells, and NK cells is aggravated by confusion in the literature regarding terminology and diagnostic criteria for individual disease entities and clinical syndromes. Meeting participants concluded that the term CAEBV should be applied to systemic LPDs that are not frank lymphomas and that arise during primary infection and persist for over 6 months. In addition, the nature of the EBV-infected cell, B, T, or NK, should be specified in all instances. CAEBV of B-cell origin also has been referred to as chronic (or persistent) infectious mononucleosis, which is a distinct entity from the chronic fatigue syndrome. The term 'systemic EBV-positive T-cell LPD', as adopted by the WHO classification, is the preferred pathologic designation over CAEBV for those cases that are clearly clonal, as they are generally associated with an aggressive clinical course and require aggressive treatment. These cases may, however, arise in the background of CAEBV. HV, which may be clonal, has a chronic and protracted clinical course and may regress spontaneously in adult life. As it has distinctive clinical and pathological features, the term HV is preferred over CAEBV for patients with these features. Criteria for the distinction of HV and HV-like lymphoma remain to be defined. Severe mosquito bite allergy appears to be a related syndrome, but is usually of NK cell origin.

Participants proposed the establishment of an international consortium to collect further clinical outcome data on CAEBV and related disorders. In addition, a proposed biobank will

allow studies of cellular immunity, gene expression profiling, and sequencing of candidate genes. It is hoped that these studies will identify new pathways involved in the pathogenesis of these diseases and lead to multicenter international clinical trials to evaluate novel therapies for these diseases.

## funding

Intramural Research Programs of the Center for Cancer Research: National Cancer Institute; National Institute of Allergy and Infectious Diseases; Office of Rare Diseases at the National Institutes of Health.

## acknowledgements

We thank the participants of the meeting: Jeffrey I. Cohen, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Elaine S. Jaffe, National Cancer Institute, Bethesda, MD (organizers); Carlos Barrionuevo, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Kishor Bhatia, National Cancer Institute, Bethesda, MD; John K. C. Chan, Queen Elizabeth Hospital, Kowloon, Hong Kong; Janet Dale, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Kieron Dunleavy, National Cancer Institute, Bethesda, MD; Nancy Lee Harris, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Helen Heslop, Baylor College of Medicine, Houston, TX; James Jones, Centers for Disease Control and Prevention, Atlanta, GA; Shannon Kenney, University of Wisconsin, Madison, WI; Rajiv Khanna, Queensland Institute of Medical Research, Brisbane, Australia; Elliot Kieff, Harvard University, Boston, MA; Hiroshi Kimura, Nagoya University, Nagoya, Japan; Y.-H. Ko, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Richard Little, National Cancer Institute, Bethesda, MD; Shigeo Nakamura, Nagoya University, Nagoya, Japan; Koichi Ohshima, Kurume University, Kurume, Japan; Miguel A. Piris, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Stefania Pittaluga, National Cancer Institute, Bethesda, MD; Leticia Quintanilla-Martinez, University of Tubingen, Tubingen, Germany; Koneti Rao, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Alan Rickinson, University of Birmingham, Birmingham, England; Cliona Rooney, Baylor College of Medicine, Houston, TX; John Sixbey, Louisiana State University, Shreveport, Louisiana; John Sullivan, University of Massachusetts, Worcester, MA; Steven Swerdlow, University of Pittsburgh, Pittsburgh, PA; Giovanna Tosato, National Cancer Institute, Bethesda, MD; Larry Weiss, City of Hope National Medical Center, Duarte, CA; Denise Whitby, National Cancer Institute; Wyndham Wilson, National Cancer Institute, Bethesda, MD; Zhou Xiaoge Beijing, Friendship Hospital, Beijing, China; Robert Yarchoan, National Cancer Institute, Bethesda, MD; Tadashi Yoshinino, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.

## references

1. Straus SE. The chronic mononucleosis syndrome. *J Infect Dis* 1988; 157: 405-412.

2. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. *Blood* 2001; 98: 280–286.
3. Risdall RJ, McKenna RW, Nesbit ME et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. *Cancer* 1979; 44: 993–1002.
4. Su IJ, Hsieh HJ, Lee CY. Histiocytic medullary reticulosis: a lethal form of primary EBV infection in young children in Taiwan [letter]. *Lancet* 1989; 1: 389.
5. Lay JD, Tsao CJ, Chen JY et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. *J Clin Invest* 1997; 100: 1969–1979.
6. Teruya-Feldstein J, Setsuda J, Yao X et al. MIP-1alpha expression in tissues from patients with hemophagocytic syndrome. *Lab Invest* 1999; 79: 1583–1590.
7. Oyama T, Ichimura K, Suzuki R et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. *Am J Surg Pathol* 2003; 27: 16–26.
8. Shimoyama Y, Oyama T, Asano N et al. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review. *J Clin Exp Hematop* 2006; 46: 1–4.
9. Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. *Blood* 2007; 110: 972–978.
10. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer 2008.
11. Bharadwaj M, Burrows SR, Burrows JM et al. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. *Blood* 2001; 98: 2588–2589.
12. Silins SL, Sherritt MA, Silleri JM et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. *Blood* 2001; 98: 3739–3744.
13. Kanegane H, Wakiguchi H, Kanegane C et al. Viral interleukin-10 in chronic active Epstein-Barr virus infection. *J Infect Dis* 1997; 176: 254–257.
14. Teruya-Feldstein J, Jaffe ES, Burd PR et al. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. *Blood* 1997; 90: 4099–5105.
15. Wong CK, Wong BCK, Chan KCA et al. Cytokine profile in fatal human immunodeficiency virus-tuberculosis Epstein-Barr virus-associated hemophagocytic syndrome. *Arch Int Med* 2007; 167: 1901–1903.
16. Tang YI, Liao C, Xu XJ et al. Detection of Th1/Th2 cytokines is useful for the quick and early diagnosis of hemophagocytic syndrome in children. *Blood* 2007; 110: 88B–89B.
17. Katano H, Ali MA, Patera AC et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. *Blood* 2004; 103: 1244–1252.
18. Oyama T, Yamamoto K, Asano N et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. *Clin Cancer Res* 2007; 13: 5124–5132.
19. Shimoyama Y, Yamamoto K, Asano N et al. Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. *Cancer Sci* 2008; 99: 1085–1091.
20. Asano N, Yamamoto K, Tamaru J-I. Age-related EBV-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classical Hodgkin's lymphoma in elderly patients. *Blood* 2009; 113: 2629–2636.
21. Schragger J, Pittaluga S, Raffeld M, Jaffe ES. EBV reactivation syndromes in adults without known immunodeficiency. *Mod Pathol* 2009; 22 (Suppl 1): 285A.
22. Kojima M, Kashimura M, Itoh H et al. Epstein-Barr virus-related reactive lymphoproliferative disorders in middle-aged or elderly patients presenting with atypical features. A clinicopathological study of six cases. *Pathol Res Pract* 2007; 203: 587–591.
23. Guinee DJ, Jaffe E, Kingma D et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. *Am J Surg Pathol* 1994; 18: 753–764.
24. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology, and clinical implications. *Cancer Surv* 1997; 30: 233–248.
25. Wilson WH, Kingma DW, Raffeld M et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. *Blood* 1996; 87: 4531–4537.
26. Dunleavy K, Janik J, Cohen J et al. Study of the treatment and biology of lymphomatoid granulomatosis (LYG); a rare EBV lymphoproliferative disorder. *Ann Oncol* 2005; 16 (Suppl 5): 59.
27. Fauci AS, Haynes BF, Costa J et al. Lymphomatoid granulomatosis: prospective clinical and therapeutic experience over 10 years. *N Engl J Med* 1982; 306: 68–74.
28. Katzenstein AA, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. *Cancer* 1979; 43: 360–373.
29. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? *Rev Med Virol* 2006; 16: 251–261.
30. Kimura H, Morishima T, Kanegane H et al. Prognostic factors for chronic active Epstein-Barr virus infection. *J Infect Dis* 2003; 187: 527–533.
31. Iwatsuki K, Ohtsuka M, Akiba H, Kaneko F. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. *J Am Acad Dermatol* 1999; 40: 283–284.
32. Iwatsuki K, Xu Z, Takata M et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. *Br J Dermatol* 1999; 140: 715–721.
33. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype. Distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious-mononucleosis—implications for the interindividual infection route of Epstein-Barr-virus. *Blood* 1995; 85: 744–750.
34. Isobe Y, Sugimoto K, Yang L et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. *Cancer Res* 2004; 64: 2167–2174.
35. Tabiasco J, Vercellone A, Meggetto F et al. Acquisition of viral receptor by NK cells through immunological synapse. *J Immunol* 2003; 170: 5993–5998.
36. Kimura H, Hoshino Y, Hara S et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. *J Infect Dis* 2005; 191: 531–539.
37. Aoukaty A, Lee IF, Wu J, Tan R. Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells. *J Clin Immunol* 2003; 23: 141–145.
38. Gotoh K, Ito Y, Shibata-Watanabe Y et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. *Clin Infect Dis* 2008; 46: 1525–1534.
39. Sato E, Ohga S, Kuroda H et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. *Am J Hematol* 2008; 83: 721–727.
40. Okamura T, Hatsukawa Y, Arai H et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. *Lancet* 2000; 356: 223–224.
41. Kawa K, Okamura T, Yasui M et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. *Crit Rev Oncol Hematol* 2002; 44: 251–257.
42. Ohshima K, Kimura H, Yoshino T et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. *Pathol Int* 2008; 58: 209–217.
43. Quintanilla-Martinez L, Kumar S, Fend F et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. *Blood* 2000; 96: 443–451.
44. Cho EY, Kim KH, Kim WS et al. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. *J Korean Med Sci* 2008; 23: 185–192.
45. Su IJ, Lin DT, Hsieh HC et al. Fatal primary Epstein-Barr virus infection masquerading as histiocytic medullary reticulosis in young children in Taiwan. *Hematol Pathol* 1990; 4: 189–195.

46. Park S, Kim K, Kim WS et al. Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. *Virchows Arch* 2008; 453: 155–163.
47. Chen G, Tai AK, Lin M et al. Increased proliferation of CD8+ T cells in SAP-deficient mice is associated with impaired activation-induced cell death. *Eur J Immunol* 2007; 37: 663–674.
48. Barrionuevo C, Anderson VM, Zevallos-Giampietri E et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. *Appl Immunohistochem Mol Morphol* 2002; 10: 7–14.
49. Katagiri Y, Mitsuhashi Y, Kondo S et al. Hydroa vacciniforme-like eruptions in a patient with chronic active EB virus infection. *J Dermatol* 2003; 30: 400–404.
50. Cho KH, Lee SH, Kim CW et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. *Br J Dermatol* 2004; 151: 372–380.
51. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV-positive T-cell lymphoproliferative disorders of childhood. In Swerdlow SH, Campo E, Harris NL et al. : *Poietic and Lymphoid Tissues*, 4th edition. Lyon, France: International Agency for Research on Cancer 2008; 278–280.
52. Satoh M, Oyama N, Akiba H et al. Hypersensitivity to mosquito bites with natural-killer cell lymphocytosis: the possible implication of Epstein-Barr virus reactivation. *Eur J Dermatol* 2002; 12: 381–384.
53. Zhang Y, Nagata H, Ikeuchi T et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. *Br J Haematol* 2003; 121: 805–814.
54. Savoldo B, Huls MH, Liu Z et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. *Blood* 2002; 100: 4059–4066.
55. Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). *Blood* 2006; 108: 2942–2949.
56. Louis CU, Straathof K, Bollard CM et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. *Blood* 2009; 113: 2442–2450.
57. Gottschalk S, Edwards OL, Sili U et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. *Blood* 2003; 101: 1905–1912.
58. Bollard CM, Straathof KC, Huls MH et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. *J Immunother* 2004; 27: 317–327.
59. Hale GA, Bowman LC, Woodard JP et al. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. *Bone Marrow Transplant* 2003; 31: 981–986.
60. Cooper N, Rao K, Gilmour K et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. *Blood* 2006; 107: 1233–1236.
61. Hierro L, Diez-Dorado R, Diaz C et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. *Liver Transpl* 2008; 14: 1185–1193.
62. He Y, Cai S, Zhang G et al. Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. *Virus Res* 2008; 135: 175–180.
63. Perrine SP, Hermine O, Small T et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. *Blood* 2007; 109: 2571–2578.
64. Feng WH, Israel B, Raab-Traub N et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. *Cancer Res* 2002; 62: 1920–1926.
65. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. *Cancer Res* 2006; 66: 8762–8769.
66. Srimatkandada P, Loomis R, Carbone R et al. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases. *Eur J Haematol* 2008; 80: 407–418.
67. Miyake A, Dewan MZ, Ishida T et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. *Microbes Infect* 2008; 10: 748–756.
68. Nepomuceno RR, Balatoni CE, Natkunam Y et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. *Cancer Res* 2003; 63: 4472–4480.

# Identification of Epstein-Barr Virus (EBV)-Infected Lymphocyte Subtypes by Flow Cytometric In Situ Hybridization in EBV-Associated Lymphoproliferative Diseases

Hiroshi Kimura,<sup>1</sup> Kanae Miyake,<sup>1</sup> Yohei Yamauchi,<sup>1</sup> Kana Nishiyama,<sup>1</sup> Seiko Iwata,<sup>1</sup> Keiji Iwatsuki,<sup>3</sup> Kensei Gotoh,<sup>2</sup> Seiji Kojima,<sup>2</sup> Yoshinori Ito,<sup>2</sup> and Yukihiro Nishiyama<sup>1</sup>

Departments of <sup>1</sup>Virology and <sup>2</sup>Pediatrics, Nagoya University Graduate School of Medicine, Nagoya; <sup>3</sup>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

To diagnose Epstein-Barr virus (EBV)-associated diseases and to explore the pathogenesis of EBV infection, not only must the EBV load be measured, but EBV-infected cells must also be identified. We established a novel flow cytometric in situ hybridization assay to detect EBV<sup>+</sup> suspension cells using a peptide nucleic acid probe specific for EBV-encoded small RNA (EBER). By enhancing fluorescence and photostability, we successfully stained EBER and surface antigens on the same cells. In 3 patients with hydroa vacciniforme-like lymphoproliferative disease, we demonstrated that 1.7%–25.9% of peripheral lymphocytes were infected with EBV and specifically identified these lymphocytes as CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup>  $\gamma\delta$  T cell receptor-positive T cells. The results indicate that this novel and noninvasive assay is a direct and reliable method of characterizing EBV-infected lymphocytes that can be used not only to diagnose EBV infection but also to clarify the pathogenesis of EBV-associated diseases.

Epstein-Barr virus (EBV) is a ubiquitous virus and occasionally causes infectious mononucleosis in primary infection. In rare cases, chronic active EBV infection develops in apparently immunocompetent hosts [1–3]. EBV preferentially infects B cells through CD21 and HLA class II molecules and establishes latent infection in memory B cells [4]. Several types of B cell-origin lymphomas or lymphoproliferative diseases, including Burkitt lymphoma, Hodgkin lymphoma, primary central nervous system lymphoma, and opportunistic B cell lymphoproliferative disorders, are etiologi-

cally linked to EBV infection [2, 3, 5]. EBV also infects T cells and natural killer (NK) cells and is associated with T/NK lymphoproliferative diseases and lymphoma or leukemia, such as EBV-related hemophagocytic lymphohistiocytosis, systemic EBV<sup>+</sup> T cell lymphoproliferative disease of childhood, hydroa vacciniforme-like lymphoma, nasal NK cell lymphoma, and aggressive NK cell leukemia [2, 3, 5, 6].

Because EBV is a ubiquitous virus that latently infects various lymphocytes, simply detecting EBV is insufficient to diagnose EBV-associated diseases [7]. To diagnose EBV-associated diseases and to explore the pathogenesis of EBV infection, one must not only measure the EBV load, but one must also identify EBV-infected cells. In situ hybridization (ISH) with the EBV-encoded small RNA (EBER) is widely used to detect EBV-infected cells in tissue specimens [8, 9]. EBER is a good marker for EBV infection because it is detectable in virtually all EBV-infected cells and is expressed at very high levels, reaching 10<sup>7</sup> molecules per cell [5]. Therefore, EBER ISH is a specific and direct method of identifying EBV-infected cells in tissue specimens [9]. How-

Received 3 March 2009; accepted 6 May 2009; electronically published 21 August 2009.

Potential conflicts of interest: none reported.

Financial support: Ministry of Education, Culture, Sports, Science and Technology, Japan (grant 19591247).


Reprints or correspondence: Dr Kimura, Dept of Virology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan (hkimura@med.nagoya-u.ac.jp).

**The Journal of Infectious Diseases** 2009;200:1078–87

© 2009 by the Infectious Diseases Society of America. All rights reserved.

0022-1899/2009/20007-0010\$15.00

DOI: 10.1086/605610



**Figure 1.** Detection of Epstein-Barr virus (EBV)-encoded small RNA (EBER) by flow cytometric in situ hybridization assay. EBV<sup>+</sup> or EBV<sup>-</sup> cells were fixed, permeabilized, and hybridized with either the EBER peptide nucleic acid (PNA) probe (*shaded histograms*) or the negative control PNA probe (*open histograms*). After enhancement of fluorescent signals with Alexa Fluor 488-labeled antibodies, cells were analyzed by flow cytometry. Cell lines included the EBV<sup>+</sup> B cell lines, Raji, Daudi, lymphoblastoid cell line (LCL) 1, and LCL-2; EBV<sup>+</sup> natural killer (NK) cell lines, SNK-1, SNK-6, SNK-10, and KAI3; EBV<sup>+</sup> T cell lines, SNT-13 and SNT-16; EBV<sup>-</sup> B cell line, BJAB; EBV<sup>-</sup> NK cell line, KHYG-1; EBV<sup>-</sup> T cell lines, MOLT-4 and Jurkat. FITC, fluorescein isothiocyanate.

ever, biopsies are invasive and cannot always be performed, owing to the lack of nodal sites or difficulty of access. Because EBV-infected lymphocytes migrate in the peripheral blood in most EBV-associated lymphomas or lymphoproliferative diseases, peripheral blood lymphocytes can be examined instead of tissue specimens [7]. For this reason, applying EBER ISH to peripheral blood would allow EBV-infected cells to be identified and quantified using a more convenient and less invasive procedure.

Peptide nucleic acid (PNA) is a DNA/RNA analog capable of binding to DNA and RNA in a sequence-specific manner [10]. In PNA, nucleobases are attached to a backbone that consists of repetitive units of N-(2-aminoethyl)glycine, in contrast to the sugar-phosphate backbone of DNA/RNA. Because of the high binding affinity of PNA to DNA/RNA and its stability [11, 12], PNA probes have been used for fluorescent ISH to determine telomere lengths at chromosome ends [13–15].


In this study, we established a novel ISH method to detect EBER<sup>+</sup> suspension cells with flow cytometry using a commercially available EBER PNA probe [16]. By enhancing fluorescence and photostability and modifying the fixation and hy-

bridization steps, we successfully stained both EBER and surface antigens. With this novel flow cytometric ISH (FISH) method, we showed that EBV<sup>+</sup>  $\gamma\delta$  T cells were present in the peripheral blood of patients with hydroa vacciniforme–like lymphoproliferative disease [17], which was defined as an EBV<sup>+</sup> cutaneous T cell lymphoproliferative disease that occurs in children [6, 18].

## METHODS

**Cell lines.** The EBV<sup>+</sup> B cell lines included Raji and Daudi, both of which were derived from Burkitt’s lymphoma tissue, and 2 lymphoblastoid cell lines transformed with B95–8 EBV. BJAB, an EBV<sup>-</sup> B cell line, was used as a negative control. The EBV<sup>+</sup> T cell lines included SNT-13 and SNT-16 [19], and the EBV<sup>+</sup> NK cell lines included SNK-1, -6, and -10 [19], and KAI3 [20]. These T and NK cell lines were derived either from patients with chronic active EBV infection or from T or NK cell lymphomas. MOLT-4 and Jurkat were used as EBV<sup>-</sup> T cell lines [21], and KHYG-1 was used as an EBV<sup>-</sup> NK cell line [22].

**Patients and samples.** Three patients with hydroa vaccini-



**Figure 2.** Dual staining for surface antigens and Epstein-Barr virus (EBV)-encoded small RNA (EBER) by flow cytometric in situ hybridization assay. Cells were stained for surface antigens with phycoerythrin (PE)- or PE-cyanin 5 (PC5)-labeled monoclonal antibodies and then fixed, permeabilized, and hybridized with the EBER peptide nucleic acid probe. After enhancement of fluorescent signals, cells were analyzed by flow cytometry. The EBV<sup>+</sup> B cell line was Raji; the EBV<sup>+</sup> natural killer (NK) cell line, SNK-6; the EBV<sup>+</sup> T cell line, SNT-13; and the EBV<sup>-</sup> B cell line, BJAB.

forme-like lymphoproliferative disease and 1 patient with post-transplantation lymphoproliferative disease were enrolled in the study. As negative controls, 5 healthy volunteers who were seropositive for EBV were also enrolled. Heparinized blood samples were obtained, and peripheral blood mononuclear cells (PBMCs) were separated by density gradients. PBMCs were cryopreserved at  $-80^{\circ}\text{C}$  until analysis.


Informed consent was obtained from all patients or guardians and healthy carrier donors. The institutional review board of Nagoya University Hospital approved the use of all specimens examined in this study.

**Surface marker staining.** Cells were stained with phycoerythrin (PE)-labeled anti-CD3 (clone UCHT1; eBioscience), anti-CD8 (clone B9.11; Immunotech), anti-CD19 (clone HD37; Dako), and anti-CD56 (clone N901; Immunotech) monoclonal antibodies and PE-cyanin 5 (PC5)-labeled anti-CD2 (clone 39C1.5; Immunotech), anti-CD4 (clone 13B8.2; Immunotech), anti-CD16 (clone 3G8; Immunotech), anti-CD56 (clone N901; Immunotech), anti-HLA-DR (clone IMMU357; Immunotech), anti- $\alpha\beta$  T cell receptor (TCR) (clone IP26; eBioscience), and anti-TCR $\gamma\delta$  (clone IMMU510; Immunotech) monoclonal antibodies for 1 h at  $4^{\circ}\text{C}$ . Isotype-matched monoclonal mouse

immunoglobulin (Ig) G antibodies were used in each experiment as controls.


**PNA probes.** The EBER PNA probe, Y5200, was purchased from Dako. The Y5200 probe is a mixture of 4 different fluorescein-labeled PNA probes complementary to EBER [16]. The negative control PNA probe (Dako), which consists of fluorescein-conjugated random PNA probes, was used as a negative control. The positive control PNA probe (Dako) directed against glyceraldehyde 3-phosphate dehydrogenase was used as a positive control. Each PNA probe was labeled with fluorescein isothiocyanate (FITC).

**FISH technique.** The following experiments were performed in 1.5-mL microcentrifuge tubes (Corning). For surface marker staining, cells were stained with the appropriate antibodies before fixation and hybridization. Cultured cells ( $2 \times 10^5$ ) or PBMCs ( $5 \times 10^5$ ) were fixed with 1% (vol/vol) acetic acid in 4% paraformaldehyde/phosphate buffered saline (PBS) for 40 min at  $4^{\circ}\text{C}$ . After being washed once with PBS, cells were permeabilized in 50  $\mu\text{L}$  of 0.5% Tween 20/PBS at room temperature. Formamide, buffer, and water were added to the cells in permeabilization buffer so that the final formamide and buffer concentrations were the same as the hy-



**Figure 3.** Detection of dual staining for surface antigens and Epstein-Barr virus (EBV)-encoded small RNA (EBER) by confocal microscopy. Cells were stained for surface antigens with phycoerythrin (PE)- or PE-cyanin 5 (PC5)-labeled monoclonal antibodies and then fixed, permeabilized, and hybridized with the EBER peptide nucleic acid probe. After enhancement of fluorescent signals, cells were mounted on glass slides and analyzed by confocal immunofluorescence microscopy. The EBV<sup>+</sup> B cell line was Raji; the EBV<sup>-</sup> B cell line, BJAB; and the EBV<sup>+</sup> T cell line, SNT-13. Bars, 10  $\mu$ m.






**Figure 4.** Minimum detection level of cells positive for Epstein-Barr virus (EBV) by flow cytometric in situ hybridization assay. EBV<sup>+</sup> Raji cells and EBV<sup>-</sup>BJAB cells were mixed at various ratios, stained with phycoerythrin (PE)-labeled anti-CD19 antibody, and then fixed, permeabilized, and hybridized with the EBV-encoded small RNA (EBER) peptide nucleic acid (PNA) probe. After enhancement of fluorescent signals, the cells were analyzed by flow cytometry. The ratio of Raji to BJAB cells is shown above each quadrant. Numbers in quadrants indicate percentages of CD19<sup>+</sup>EBER<sup>+</sup> cells.

bridization solution (6% [wt/vol] dextran sulfate, 10 mmol/L sodium chloride, 17.5% [vol/vol] formamide, 0.061% [wt/vol] sodium pyrophosphate, 0.12% [wt/vol] polyvinylpyrrolidone, 0.12% [wt/vol] Ficoll, 5 mmol/L disodium ethylenediaminetetraacetic acid, 50 mmol/L tris(hydroxymethyl) aminomethane [pH 7.5]). The cells were resuspended in 45  $\mu$ L of hybridization solution containing 12 nmol/L of the EBER PNA probe, negative control PNA probe, or positive control PNA probe, all FITC labeled. Hybridization was carried out for 1 h at 56°C.

Then cells were washed twice (for 10 and 30 min) with 0.5% Tween 20/PBS at 56°C. To enhance fluorescence and photostability, the Alexa Fluor 488 Signal Amplification Kit (Molecular Probes) was used. The kit protocol had 2 steps, using Alexa Fluor 488 rabbit anti-FITC to bind FITC-labeled probes and Alexa Fluor 488 goat anti-rabbit IgG for further enhancement.

Stained cells were analyzed using a FACSCalibur flow cytometer and CellQuest software, version 5.2.1 (Becton Dickinson). For cell lines, live gating was determined by forward



**Figure 5.** Correlation between the percentage of cells positive for Epstein-Barr virus (EBV)-encoded small RNA (EBER) and input EBV<sup>+</sup> cells. EBV<sup>+</sup> and EBV<sup>-</sup> cells were mixed at various ratios and analyzed by flow cytometric in situ hybridization assay. Each experiment (exp.) was done in triplicate. *A*, B cell lines included Raji (EBV<sup>+</sup>) and BJAB (EBV<sup>-</sup>). *B*, T cell lines included SNT13 (EBV<sup>+</sup>) and Jurkat (EBV<sup>-</sup>).

and side scatter profiles. For PBMCs, lymphocytes were gated by standard forward and side scatter profiles [23]. Up to 50,000 events were acquired for each analysis.

**Confocal microscopy.** Cells were resuspended in 20  $\mu$ L of PermaFluor mounting medium (Thermo) and mounted on-to glass slides with coverslips. Samples were examined under an LSM 510 confocal immunofluorescence microscope (Carl Zeiss) [24].

**Analyses of EBV DNA.** Viral load was examined in the PBMCs of all patients. DNA was extracted from  $1 \times 10^6$  PBMCs using a QIAamp Blood Kit (Qiagen). Real-time quantitative polymerase chain reaction (PCR) with a fluorogenic probe was performed as described elsewhere [25]. The amount of EBV DNA was calculated as the number of virus copies per microgram of PBMC DNA or per milliliter of whole blood.

To determine which cells harbored EBV, PBMCs were fractionated into CD3<sup>+</sup>, CD19<sup>+</sup>, CD56<sup>+</sup>, TCR $\alpha\beta$ <sup>+</sup>, and TCR $\gamma\delta$ <sup>+</sup> cells using an immunobead method (IMag Cell Separation System; Becton Dickinson) with 97%–99% purity. The fractionated cells were analyzed by real-time quantitative PCR and compared with PBMCs [26]. The clonality of EBV was determined using Southern blotting with a terminal repeat probe, as described elsewhere [27].

**Rearrangement of the TCR gene.** TCR gene rearrangement was determined by multiplex PCR assays using the T Cell Gene Rearrangement/Clonality assay (InVivoScribe Technologies), which was developed and standardized in a European BIOMED-2 collaborative study [28, 29].

## RESULTS


**FISH assay to detect EBER.** EBV<sup>+</sup> or EBV<sup>-</sup> cell lines were fixed, permeabilized, and hybridized with the EBER PNA probe

or negative control PNA probe. After enhancement of fluorescent signals, cells were analyzed by flow cytometry. On the basis of flow cytometry, Raji cells had a significant increase in fluorescence intensity of the EBER PNA probe compared with the negative control PNA probe (Figure 1). Other EBV<sup>+</sup> B cell lines (Daudi, lymphoblastoid cell line [LCL] 1, and LCL-2) were consistently positive for EBER. In addition to B cell lines, NK cell lines (SNK-1, SNK-6, SNK-10, and KAI3) and EBV<sup>+</sup> T cell lines (SNT-13 and SNT-16) were also positive for EBER, whereas EBV<sup>-</sup> B cell (BJAB), NK cell (KHYG-1), and T cell (MOLT-4 and Jurkat) lines were negative for EBER.

**Dual staining for surface antigens and EBER.** To identify and characterize EBV-infected cells, surface lymphocyte antigens and nuclear EBER must be detected simultaneously. To this end, we first stained surface antigens with PE- or PC5-labeled monoclonal antibodies and then fixed and hybridized the cells with the EBER PNA probe. After enhancement of fluorescence intensity with Alexa Fluor 488 antibodies, both Alexa Fluor 488-labeled EBER and PE- or PC5-labeled surface antigens were detected by flow cytometry. As shown in Figure 2, the EBV<sup>+</sup> B cell line, Raji, was positive for Alexa Fluor 488-labeled EBER, PE-labeled CD19, and PC5-labeled HLA-DR, but negative for CD2, CD3, CD16, and CD56. In contrast, the EBV<sup>+</sup> NK cell line, SNK-6, was positive for EBER, CD2, CD56, and HLA-DR, but negative for CD3 and CD19. The EBV<sup>+</sup> T cell line, SNT-13, was positive for EBER, CD2, and CD3, but negative for CD16, CD19, CD56, and HLA-DR. The EBV<sup>-</sup> cell line BJAB was negative for EBER, but surface CD19 and HLA-DR antigens were detected (Figure 2).

The dual staining for surface antigens and EBER was further confirmed by confocal microscopy (Figure 3). PE-labeled CD19 and PC5-labeled HLA-DR were present on the surface of both Raji and BJAB cells, whereas Alexa Fluor 488-labeled EBER was specifically detected in the nucleus of Raji cells but not BJAB cells. In contrast, CD3 and CD2 were not present on the surface of Raji cells but were detected on the surface of the EBV<sup>+</sup> T cell line, SNT-13.

**Sensitivity of the FISH assay in identifying EBV<sup>+</sup> cells.** To determine the lower detection limit of the FISH assay for EBV<sup>+</sup> cells, we mixed EBV<sup>+</sup> Raji and EBV<sup>-</sup> BJAB cells in various ratios and analyzed them using the FISH assay (Figure 4). When 10% of Raji cells were mixed with 90% of BJAB cells, 8.9% of CD19<sup>+</sup>EBER<sup>+</sup> cells could be separated from CD19<sup>+</sup>EBER<sup>-</sup> cells using the FISH assay. Consistently, as the Raji/BJAB ratio decreased, the percentage of CD19<sup>+</sup>EBER<sup>+</sup> cells also decreased. EBER<sup>+</sup> cells could be quantified down to a ratio of 1:10,000 (Raji, 0.01%, CD19<sup>+</sup>EBER<sup>+</sup> cells, 0.013%), although the population of CD19<sup>+</sup>EBER<sup>+</sup> cells was not so clear at this ratio. When 0.001% of Raji cells were mixed with BJAB cells, the percentage of CD19<sup>+</sup>EBER<sup>+</sup> cells was almost equal to 100% of



**Figure 6.** Quantification and identification of Epstein-Barr virus (EBV)-infected lymphocytes in patients with EBV-related lymphoproliferative diseases by flow cytometric in situ hybridization assay. Peripheral blood mononuclear cells were stained with phycoerythrin (PE)-labeled or PE-cyanin 5 (PC5)-labeled monoclonal antibodies and then fixed, permeabilized, and hybridized with the EBV-encoded small RNA (EBER) peptide nucleic acid (PNA) probe. After enhancement of fluorescent signals, the cells were analyzed by flow cytometry. Numbers in histograms represent percentages of EBER<sup>+</sup> lymphocytes in the total lymphocyte population. EBER<sup>+</sup> lymphocytes (red) and EBER<sup>-</sup> lymphocytes (gray) were gated and plotted on quadrants as PE-labeled and PC5-labeled surface antigens. Numbers in quadrants indicate percentages of EBER<sup>+</sup> cells for each surface immunophenotype. A healthy EBV-seropositive donor served as the control; patients 1–3 had hydroa vacciniforme-like EBV-associated T lymphoproliferative disease, and patient 4 had posttransplantation B cell lymphoproliferative disease. FITC, fluorescein isothiocyanate; TCR, T cell receptor.

BJAB cells (0.003% vs 0.003%), suggesting that the FISH assay was not quantitative at these ratios.

To confirm the accuracy and reproducibility of the FISH assay, we performed the mixing experiments (Raji, EBV<sup>+</sup> B cell line; BJAB, EBV<sup>-</sup> B cell line) 2 more times and additional mixing experiments (SNT13, EBV<sup>+</sup> T cell line; Jurkat, EBV<sup>-</sup> T cell line) in triplicate. The resulting correlations between the percentage of EBER<sup>+</sup> cells observed by FISH and the percentage of actual input EBV<sup>+</sup> cells are shown in Figure 5. These data show a clear correlation at 0.1%–10%, indicating that the assay was able to detect  $\geq 0.1\%$  of the EBV<sup>+</sup> cells accurately and reproducibly.

**Application of the FISH assay to human PBMCs.** PBMCs were obtained from 5 healthy volunteer donors and analyzed

using the FISH assay. All donors were seropositive for EBV, but EBV DNA was not detected in their PBMCs by real-time PCR. Using the FISH assay, EBER<sup>+</sup> cells were not detected in any of the donors, whereas the positive control PNA probe directed against glyceraldehyde 3-phosphate dehydrogenase was positive for all PBMCs (data not shown). Dual staining with antibodies to surface antigens and PNA probes showed that most lymphocyte markers were successfully detected and that distinct lymphocyte subsets could be separated, although some surface antigen intensities were not sufficient to separate certain populations (eg, CD56 and TCR $\alpha\beta$ ). A representative result is shown in Figure 6 (control).

Next, we applied the FISH assay to 3 patients with hydroa vacciniforme-like lymphoproliferative disease. These patients

**Table 1. Clinical and Virologic Characteristics of Patients with Epstein-Barr Virus (EBV)-Associated Lymphoproliferative Diseases**

Patient	Sex	Age, years	Age at onset, years	Diagnosis	EBV clonality	TCR gene rearrangement	EBV DNA, copies/ $\mu$ g DNA					EBV DNA, copies/mL whole blood	
							PBMCs	CD3 <sup>+</sup>	TCR $\alpha\beta$ <sup>+</sup>	TCR $\gamma\delta$ <sup>+</sup>	CD19 <sup>+</sup>		CD3 <sup>-</sup> CD56 <sup>+</sup>
1	M	16	5	Hydroa vacciniforme	Monoclonal	V $\gamma$ If,V $\gamma$ 10/J $\gamma$ ,V $\delta$ /J $\delta$	6100	16,380	8310	101,210	ND	860	11,850
2	M	11	5	Hydroa vacciniforme	Monoclonal	V $\gamma$ If,V $\gamma$ 10/J $\gamma$ ,V $\delta$ /J $\delta$	10,040	13,230	210	87,420	ND	240	ND
3	M	6	3	Hydroa vacciniforme	Monoclonal	V $\delta$ /J $\delta$	41,760	46,730	6400	190,100	9090	6400	ND
4	M	6	6	PTLD	ND	ND	22,020	920	ND	ND	91,990	7290	47,660

**NOTE.** ND, not done; PBMCs, peripheral blood mononuclear cells; PTLD, posttransplantation lymphoproliferative disease; TCR, T cell receptor.

had no symptoms aside from photosensitivity and papulovesicular eruptions on their faces or arms. Skin biopsies were performed in patients 1 and 3. Small lymphoid cells without marked atypia infiltrated both the dermis and epidermis and were positive for EBER. These findings were compatible with hydroa vacciniforme-like lymphoproliferative disease, according to the World Health Organization classification [6]. The infiltrating cells were CD3<sup>+</sup> but CD56<sup>-</sup>, indicating that they were T cells; further immunophenotyping for TCR $\alpha\beta$  and TCR $\gamma\delta$  was not performed. Extremely high amounts of EBV DNA with monoclonality were detected in the 3 patients' peripheral blood (Table 1). The clonality of the T cells was confirmed based on TCR gene rearrangement. Using the FISH assay, EBER<sup>+</sup> lymphocytes were detected in their PBMCs, with a frequency of 1.7% in patient 1, 4.8% in patient 2, and 25.9% in patient 3 (Figure 6). We repeated the FISH assay for patients 2 and 3 and obtained similar percentages of EBV<sup>+</sup> cells (patient 2, 5.0%; patient 3, 20.7%). EBER<sup>+</sup> lymphocytes were gated and plotted by PE-labeled surface antigens and PC5-labeled surface antigens. Most EBER<sup>+</sup> lymphocytes were CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup>TCR $\gamma\delta$ <sup>+</sup> T cells in the 3 patients examined. HLA-DR was expressed in EBER<sup>+</sup> lymphocytes from patients 2 and 3. To confirm these results, we applied an immunobead method to sort PBMCs into CD3<sup>+</sup>, TCR $\alpha\beta$ <sup>+</sup>, TCR $\gamma\delta$ <sup>+</sup>, CD19<sup>+</sup>, and CD3<sup>-</sup>CD56<sup>+</sup> fractions and used quantitative real-time PCR to quantify EBV DNA in each fraction. The quantity of EBV DNA was high in the CD3<sup>+</sup> and TCR $\gamma\delta$ <sup>+</sup> fractions but not in the CD19<sup>+</sup>, CD3<sup>-</sup>CD56<sup>+</sup>, or TCR $\alpha\beta$ <sup>+</sup> fractions (Table 1). For comparison, PBMCs from a patient with posttransplantation B cell lymphoproliferative disease were analyzed by both the FISH assay (Figure 6) and immunobead sorting, followed by EBV DNA quantification (Table 1). Both assays indicated that B cells in the peripheral blood of the patient were EBV<sup>+</sup>, confirming the reliability of the FISH assay.

## DISCUSSION

In this study, we established a novel FISH assay to directly quantify and simultaneously characterize EBV-infected lymphocytes using a commercially available EBER PNA probe. The probe is currently used to detect EBV-infected cells in formalin-fixed, paraffin-embedded tissue specimens. Just et al [16] also used this probe in a FISH assay. Crouch et al [30] used oli-

gonucleotide probes directed against EBER in a FISH assay and succeeded in simultaneously detecting both EBER and surface antigens. However, both of these studies used FISH assays only with cell lines, and subsequent application to human PBMCs has not been reported. We preliminarily tested the EBER PNA probe with clinical specimens, but the fluorescence intensity of the probe was not sufficient to separate EBV<sup>+</sup> peripheral blood cells from EBV<sup>-</sup> cells (data not shown). By enhancing fluorescence and photostability and modifying the fixation and hybridization steps, we successfully stained both EBER and surface antigens, not only in cell lines but also in human PBMCs. The order of immunophenotyping and ISH is important. We tried the reverse method (ISH preceded by surface immunophenotyping), but no surface antigens were detected by the monoclonal antibodies after ISH (data not shown).

This is a direct method to quantify EBV-infected cells and simultaneously characterize the infected cell phenotype, which helps not only to diagnose EBV-associated diseases but also to select monoclonal antibody-based therapy, such as anti-CD20 (rituximab) or anti-CD52 (Campath-1). We stained only surface lymphocyte markers in this study, but additional surface or intracellular molecules, such as cell adhesion markers, cytotoxic granules, or cytokines, will enable us to characterize and examine the function of EBV-infected lymphocytes. Furthermore, this method can be applied not only to peripheral blood but also to bone marrow and other body fluids, such as ascites, pleural effusions, and cerebrospinal fluid. In addition, FISH can be used for flow cytometric sorting of EBER<sup>+</sup> cells, which will further expand the ability to isolate and extensively study EBV-infected lymphocytes.

As a noninvasive method to diagnose and monitor EBV-associated lymphoproliferative diseases, measuring viral load in the peripheral blood is a necessary clinical tool. Quantitative PCR assays, such as real-time PCR, are the easiest and most reliable way to measure EBV load and are widely used for diagnosing and managing EBV-associated lymphoproliferative diseases, such as posttransplantation lymphoproliferative disease [7, 31–33]. The FISH assay has some disadvantages compared with quantitative PCR. First, the FISH assay has a lower sensitivity, although it can detect  $\geq 0.1\%$  of EBV-infected cells. Second, this assay cannot be applied to EBV-associated diseases

in which EBV-infected cells do not migrate into the peripheral blood, such as nasopharyngeal carcinoma or Hodgkin lymphoma [7, 34, 35]. Another unresolved problem with this assay is that after hybridization, the fluorescent signals of some surface antigens and antibodies were weak and cell separation was incomplete (eg, CD56 and TCR $\alpha\beta$  in Figure 6). We have not clarified this phenomenon completely, but we believe that antigen-antibody complexes were degraded or detached under the harsh hybridization conditions. The extent of this decrease in fluorescent signals differed among antibodies. We screened several monoclonal antibodies with different fluorochromes from different manufacturers for each surface antigen and then selected the best antibodies, as listed in Methods. Thus, selecting the appropriate antibody is important when performing the FISH assay. This problem may be overcome by using better antibodies, cross-linking antibodies or biotin-avidin enhancement, or modifying the fixation or hybridization steps, but the combination of antibodies and the hybridization conditions used in this study are sufficient to separate B, T, and NK cells from other populations.

Hydroa vacciniforme-like lymphoproliferative disease is an EBV<sup>+</sup> cutaneous malignancy associated with photosensitivity [6]. Although this condition is rare, it affects children and adolescents from Asia and Latin America [36–39]. It is characterized by a papulovesicular eruption that generally proceeds to ulceration and scarring. In some cases, systemic symptoms may be present, including fever, wasting, lymphadenopathy, and hepatosplenomegaly. In hydroa vacciniforme-like eruption, T cells with cytotoxic molecules often infiltrate the superficial dermis and subcutaneous tissues [39]. Most persons with this condition have clonal rearrangement of the TCR genes. EBV in these patients is also monoclonal, as shown terminal repeat analysis. These results indicate that clonal expansion of EBV-infected T cells causes the disease. However, the reported phenotypes of these T cells are variable, and both CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets have been reported [37, 40]. Most studies lack direct confirmation of these cell populations by double-staining with EBER and surface antigens.

In 3 patients with hydroa vacciniforme-like lymphoproliferative disease, we demonstrated that 1.7%–25.9% of peripheral lymphocytes were EBER<sup>+</sup> and that these lymphocytes were primarily CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup>TCR $\gamma\delta$ <sup>+</sup> T cells. This is the first study to determine the precise phenotype of EBV-infected lymphocytes in hydroa vacciniforme-like lymphoproliferative disease.  $\gamma\delta$  T cells are the major T cell population in the epithelium of the skin and mucosa. They secrete various cytokines and have cytolytic properties [41]. It is possible that EBV-infected  $\gamma\delta$  T cells play a central role in the formation of hydroa vacciniforme-like eruptions. The 3 patients examined in this study had no symptoms other than eruptions for several years (3–11 years), although they had a high percentage of clonal, EBV-

infected lymphocytes in their peripheral blood. The prognosis of hydroa vacciniforme-like lymphoproliferative disease has been reported to be variable, and some cases do not progress for up to 10–15 years or seem to spontaneously enter remission [39, 42]. The 3 patients in our study may be exceptional and may not be representative of this patient population. Further investigation with a larger number of patients is needed to conclude that  $\gamma\delta$  T cells are the primary EBV-infected cells in hydroa vacciniforme-like lymphoproliferative disease.

Hydroa vacciniforme-like eruption is also seen in severe chronic active EBV infection, which is caused by the clonal expansion of EBV-infected T or NK cells and seen mainly in East Asia [42–45]. These 2 conditions overlap, but their definitions are unclear [6, 46]. Because the 3 patients in the present study had only skin-restricted symptoms, they did not fulfil the classic criteria for chronic active EBV infection [47]. However, both severe chronic active EBV infection and hydroa vacciniforme-like lymphoproliferative disease develop in children and young adults from East Asia and may be caused by the clonal expansion of EBV-infected T or NK cells. To define and differentiate these diseases, additional data on EBV-associated lymphoproliferative diseases are needed. The FISH assay described in this study is a noninvasive, direct, and relatively convenient method to identify and characterize EBV-infected lymphocytes. With this novel method, we hope to further clarify the pathogenesis of EBV-associated lymphoproliferative diseases, including chronic active EBV infection, and to classify each disease more accurately.

## Acknowledgments

We thank Tatsuya Tsurumi (Aichi Cancer Center) for the Raji and Daudi cell lines, Akihiro Tomita (Nagoya University Graduate School of Medicine) for the MOLT-4 and Jurkat cell lines, and Norio Shimizu (Tokyo Medical and Dental University) and Ayako Demachi-Okamura (Aichi Cancer Center) for the SNK-1, -6, and -10 and the SNT-13 and -16 cell lines. KAI3 and KHYG-1 were obtained from the Japanese Collection of Research Bioresources. We also thank Tom Just (Dako) for providing valuable comments regarding the FISH assay.

## References

1. Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. *Ann Intern Med* 1993; 118:45–58.
2. Cohen JI. Epstein-Barr virus infection. *N Engl J Med* 2000; 343:481–92.
3. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. *Blood* 2006; 107:862–9.
4. Rickinson AB, Kieff E. Epstein-Barr virus and its replication. In: Knipe DM, Howly PM, eds. *Virology*. 5th ed. Vol. 2. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2006:2603–54.
5. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howly PM, eds. *Virology*. 5th ed. Vol. 2. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2006:2655–700.
6. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV<sup>+</sup> T-cell lymphoma of childhood. In: Swerdlow SH, Campo E, Harris NL, et al, eds. *WHO*

- classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press. 2008:278–80.
7. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. *Rev Med Virol* 2008; 18:305–19.
  8. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. *N Engl J Med* 1992; 327:1710–4.
  9. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. *Crit Rev Oncol Hematol* 2003; 45:1–36.
  10. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science* 1991; 254:1497–500.
  11. Egholm M, Buchardt O, Christensen L, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. *Nature* 1993; 365:566–8.
  12. Demidov VV, Potaman VN, Frank-Kamenetskii MD, et al. Stability of peptide nucleic acids in human serum and cellular extracts. *Biochem Pharmacol* 1994; 48:1310–3.
  13. Lansdorp PM, Verwoerd NP, van de Rijke FM, et al. Heterogeneity in telomere length of human chromosomes. *Hum Mol Genet* 1996; 5: 685–91.
  14. Zijlmans JM, Martens UM, Poon SS, et al. Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. *Proc Natl Acad Sci USA* 1997; 94:7423–8.
  15. Lansdorp PM. Telomeres, stem cells, and hematology. *Blood* 2008; 111: 1759–66.
  16. Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. *J Virol Methods* 1998; 73: 163–74.
  17. Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. *Br J Dermatol* 1999; 140:715–21.
  18. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. *Adv Anat Pathol* 2005; 12:27–34.
  19. Zhang Y, Nagata H, Ikeuchi T, et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. *Br J Haematol* 2003; 121:805–14.
  20. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy: establishment of an IL-2-dependent NK-like cell line. *Clin Exp Immunol* 1999; 115:385–92.
  21. Sahai Srivastava BI, Minowada J. Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia. *Biochem Biophys Res Commun* 1973; 51:529–35.
  22. Yagita M, Huang CL, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. *Leukemia* 2000; 14:922–30.
  23. Kuzushima K, Hoshino Y, Fujii K, et al. Rapid determination of Epstein-Barr virus-specific CD8<sup>+</sup> T-cell frequencies by flow cytometry. *Blood* 1999; 94:3094–100.
  24. Yamauchi Y, Kiriya K, Kubota N, Kimura H, Usukura J, Nishiyama Y. The UL14 tegument protein of herpes simplex virus type 1 is required for efficient nuclear transport of the alpha transactivating factor VP16 and viral capsids. *J Virol* 2008; 82:1094–106.
  25. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. *J Clin Microbiol* 1999; 37:132–6.
  26. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. *J Infect Dis* 2005; 191:531–9.
  27. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. *Blood* 2001; 98:280–6.
  28. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. *Leukemia* 2003; 17:2257–317.
  29. Sandberg Y, van Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. *J Mol Diagn* 2005; 7:495–503.
  30. Crouch J, Leitenberg D, Smith BR, Howe JG. Epstein-Barr virus suspension cell assay using in situ hybridization and flow cytometry. *Cytometry* 1997; 29:50–7.
  31. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. *Br J Haematol* 1995; 89:98–103.
  32. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. *Transpl Infect Dis* 2001; 3:79–87.
  33. Niesters HG. Molecular and diagnostic clinical virology in real time. *Clin Microbiol Infect* 2004; 10:5–11.
  34. Ambinder RF, Lin L. Mononucleosis in the laboratory. *J Infect Dis* 2005; 192:1503–4.
  35. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. *Cancer Res* 2003; 63:2028–32.
  36. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. *Appl Immunohistochem Mol Morphol* 2002; 10:7–14.
  37. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. *Br J Dermatol* 2002; 147: 587–91.
  38. Cho KH, Lee SH, Kim CW, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. *Br J Dermatol* 2004; 151:372–80.
  39. Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. *Arch Dermatol* 2006; 142:587–95.
  40. Doeden K, Molina-Kirsch H, Perez E, Warnke R, Sundram U. Hydroa-like lymphoma with CD56 expression. *J Cutan Pathol* 2008; 35:488–94.
  41. Kaufmann SH. gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? *Proc Natl Acad Sci U S A* 1996; 93:2272–9.
  42. Nitta Y, Iwatsuki K, Kimura H, et al. Fatal natural killer cell lymphoma arising in a patient with a crop of Epstein-Barr virus-associated disorders. *Eur J Dermatol* 2005; 15:503–6.
  43. Kanegane H, Nomura K, Miyawaki T, Tosato G. Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. *Crit Rev Oncol Hematol* 2002; 44:239–49.
  44. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. *J Infect Dis* 2003; 187:527–33.
  45. Katagiri Y, Mitsuhashi Y, Kondo S, Kanazawa C, Iwatsuki K, Tsunoda T. Hydroa vacciniforme-like eruptions in a patient with chronic active EB virus infection. *J Dermatol* 2003; 30:400–4.
  46. Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. *Pathol Int* 2008; 58:209–17.
  47. Straus SE. The chronic mononucleosis syndrome. *J Infect Dis* 1988; 157:405–12.

